The impact of surfactant composition and surface charge of niosomes on the oral absorption of repaglinide as a BCS II model drug

34Citations
Citations of this article
74Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Niosomes, bilayer vesicles formed by the self-assembly of nonionic surfac-tants, are receiving increasing attention as potential oral drug delivery systems but the impact of niosomal formulation parameters on their oral capability has not been studied system-atically. The aim of this study was to investigate the impact of surfactant composition and surface charge of niosomes in enhancing oral bioavailability of repaglinide (REG) as a BCS II model drug. Methods: Niosomes (13 formulations) from various nonionic surfactants having HLB in the range of 4–28 (Tweens, Spans, Brijs, Myrj, poloxamer 188, TPGS and Labrasol) were prepared and characterized concerning their loading efficiency, hydrodynamic diameter, zeta potential, drug release profile, and stability. The oral pharmacokinetics of the selected formulations were studied in rats (8 in vivo groups). Results: The results revealed that type of surfactant markedly affected the in vitro and in vivo potentials of niosomes. The Cmax and AUC values of REG after administration of the selected niosomes as well as the drug suspension (as control) were in the order of Tween 80> TPGS> Myrj 52> Brij 35> Span 60≈Suspension. Adding stearyl amine as a positive charge-inducing agent to the Tween 80-based niosomes, resulted in an additional increase in drug absorption and values of AUC and Cmax were 3.8-and 4.7-fold higher than the drug suspension, respectively. Conclusion: Cationic Tween 80-based niosomes may represent a promising platform to develop oral delivery systems for BCS II drugs.

Cite

CITATION STYLE

APA

Yaghoobian, M., Haeri, A., Bolourchian, N., Shahhosseni, S., & Dadashzadeh, S. (2020). The impact of surfactant composition and surface charge of niosomes on the oral absorption of repaglinide as a BCS II model drug. International Journal of Nanomedicine, 15, 8767–8781. https://doi.org/10.2147/IJN.S261932

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free